PDCD1 and neoplasm: Furthermore, recently, tumor immunotherapy using immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) has been developed; therefore, interactions between cancer cells and immune cells in the tumor microenvironment have become a focus of attention in gastric cancer research [2,7].